Navigation Links
ZymoGenetics Reports Results From Atacicept Phase 1b Clinical Trial,in B-Cell Chronic Lymphocytic Leukemia

SEATTLE, June 04, 2007 /PRNewswire-FirstCall/ -- ZymoGenetics, Inc. today announced that interim findings were presented from a Phase 1b clinical trial with atacicept in B-cell chronic lymphocytic leukemia (B-CLL) at the American Society of Clinical Oncology (ASCO) 2007 annual meeting. The study included intravenous administration of higher doses than had been tested in previous studies.

"We found that atacicept was well-tolerated and biologically active at all dose levels in this study, consistent with the results of our other clinical trials," said Douglas E. Williams, Ph.D., Executive Vice President and Chief Scientific Officer of ZymoGenetics. "Together with our partner Merck Serono, we will assess the results of this and our other B-cell malignancy studies, once the studies are complete, to see whether the data support moving forward in these indications."

Atacicept in B-CLL Study Design and Results

In a Phase 1b open-label, dose escalation study, 15 patients with refractory or relapsed disease were given weekly intravenous doses of atacicept ranging from 1 mg/kg to 20 mg/kg, for five weeks. Treatment with atacicept was well tolerated at all dose levels in the study. No dose limiting toxicities or serious adverse events related to study drug have been reported to date. Among the six patients given 10 mg/kg and 15 mg/kg, three (50%) showed signs of disease stabilization, using National Cancer Institute-sponsored Working Group criteria, during the treatment period. Prior to atacicept treatment, all of these patients had rapidly increasing leukocyte counts. One patient, who received 10 mg/kg, exhibited stable disease for over six months.

Biological activity of atacicept was demonstrated in these patients by reduced immunoglobulin (Ig) concentrations after treatment at all dose levels. Mean IgA, IgG and IgM concentrations decreased by 20%, 22% and 15% from baseline, respectively, af
'"/>




Page: 1 2 3

Related medicine technology :

1. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
2. Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis
3. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
4. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
5. Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
6. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
7. Cytochroma Reports Positive Phase I Clinical Data for CTA018 Injection
8. Speedel Reports Successful SPP635 Phase IIa Trial in Hypertension
9. Columbia Laboratories Reports Positive Results from Multi-dose Pharmacokinetic Study of Vaginally-administered Lidocaine
10. CytRx Reports Promising Data from Its Open-Label Extension Clinical Trial of Arimoclomol in ALS
11. Affymax Reports Phase 2 Clinical Dose Ranging Results of Once-Per-Month Hematide for the Treatment of Anemia
Post Your Comments:
(Date:10/17/2014)... 2014  UBM Medica US announces that Endocrinology ... other clinicians who treat patients with type 2 ... use of insulin .  Nearly all ... therapy – daily injections of one or more ... the function of pancreatic beta cells. Insulin is a ...
(Date:10/17/2014)... 17, 2014  Ameritox SM , the nation,s leader ... Thomas Smith , M.D., as Chief Medical Officer. ... offering scientific resources for healthcare providers, patients and managed ... positions at a variety of healthcare companies that have ... pain and behavioral health sides of Ameritox,s business. He ...
(Date:10/17/2014)... --  ndd Medical Technologies , a leader in innovative ... announced that its EasyOne Pro® is now being used ... 140,000 square foot, 44-bed hospital with many outpatient services. ... a large number of Native Americans from several tribes ... beyond. A portion of its funding comes from the ...
Breaking Medicine Technology:Endocrinology Network Features Special Coverage on Effective Use of Insulin 2Endocrinology Network Features Special Coverage on Effective Use of Insulin 3Ameritox Appoints New Chief Medical Officer 2EasyOne Pro Mobile Respiratory Testing from ndd Medical Technologies Chosen by Choctaw Nation 2
(Date:10/19/2014)... The leading review website, Top10BestSEOHosting.com, ... and GreenGeeks are the best Dedicated Server Hosting ... who want to buy high quality hosting and ... IT manager of Top10BestSEOHosting.com says, “We believe that ... for everyone. A lot of the global clients ...
(Date:10/19/2014)... Texas (PRWEB) October 20, 2014 ... development for Partial Seizure, complete with comparative analysis ... mechanism of action (MoA), route of administration (RoA) ... featured news and press releases. It also reviews ... Partial Seizure and special features on late-stage and ...
(Date:10/19/2014)... Fancyflyingfox.com, an innovative company that provides many kinds of ... of 2014 mother of the bride dresses . ... with big discounts, up to 70% off. All consumers ... this special offer. , Owing to the company’s ... of the leading brands in the global market. A ...
(Date:10/19/2014)... October 20, 2014 Stephen T. Greenberg, M.D., ... nominated for the 10th consecutive year as one of Long ... Greenberg was also been nominated as the best provider for ... nominated as best Day Spa and best Laser Treatment center ... 14th and readers can vote for the contest once per ...
(Date:10/19/2014)... 20, 2014 – The U.S. Government has initiated ... Alzheimer,s disease by 2025. However, a workgroup of ... research milestones in the U.S. Government,s National Plan ... scope, increased in scale, and adequately funded in ... of proposals by the workgroup to enlarge and ...
Breaking Medicine News(10 mins):Health News:Top10BestSEOHosting.com Considers iPage And GreenGeeks As The Best Dedicated Server Hosting Suppliers 2Health News:Partial Seizure Therapeutic Pipeline Market Review H2 2014 in a New Report Available at RnRMarketResearch.com 2Health News:Partial Seizure Therapeutic Pipeline Market Review H2 2014 in a New Report Available at RnRMarketResearch.com 3Health News:Partial Seizure Therapeutic Pipeline Market Review H2 2014 in a New Report Available at RnRMarketResearch.com 4Health News:Fancyflyingfox.com Updates Its Website With New Mother Of The Bride Dresses For 2014 2Health News:Dr. Stephen T. Greenberg – Nominated for the 10th Consecutive Year for One of Long Island’s Best Cosmetic Surgeons for 2015 by the Long Island Press 2Health News:Scientists say national Alzheimer's plan milestones must be strengthened to meet goal by 2025 2Health News:Scientists say national Alzheimer's plan milestones must be strengthened to meet goal by 2025 3Health News:Scientists say national Alzheimer's plan milestones must be strengthened to meet goal by 2025 4Health News:Scientists say national Alzheimer's plan milestones must be strengthened to meet goal by 2025 5Health News:Scientists say national Alzheimer's plan milestones must be strengthened to meet goal by 2025 6
... executives took their cholesterol lowering medication as prescribed by ... the executives who took their medication even sporadically were ... study finding also questions the prevailing wisdom that income ... University of Michigan researchers studied 1,607 executive level managers ...
... who join a sorority* are more likely to judge ... self-objectification) and display higher levels of bulimic attitudes and ... the sorority,s recruitment process. Over time, those women who ... shame. These findings, part of Ashley Marie Rolnik,s senior ...
... lose weight or exercise, study finds , TUESDAY, March ... developing diabetes apparently isn,t enough to make most people take ... April issue of the American Journal of Preventive Medicine ... said they had tried to drop pounds or boost their ...
... This is Part ... RN Employment Lifecycle: Engagement, Retention and High-performance, , ... CHARLOTTE, NC (Vocus) March 2, 2010 -- Morehead, the human capital ... The free hour-long webinar will be broadcast on Tuesday, March 23, 2010 at 1:00 p.m. ...
... , ... ... ... ...
... ... ... ... ...
Cached Medicine News:Health News:Even the boss doesn't follow the doctor's orders 2Health News:Only the beautiful need apply 2Health News:Having Prediabetes May Not Kick-Start Prevention Efforts 2Health News:Morehead Presents Webinar on "When Satisfaction Isn't Enough: Improving RN Engagement" 2Health News:Morehead Presents Webinar on "When Satisfaction Isn't Enough: Improving RN Engagement" 3Health News:Yongye International to Present at Rodman & Renshaw Annual China Investment Conference 2Health News:Yongye International to Present at Rodman & Renshaw Annual China Investment Conference 3Health News:Yongye International to Present at Rodman & Renshaw Annual China Investment Conference 4Health News:Yongye International to Present at Rodman & Renshaw Annual China Investment Conference 5Health News:Yongye International to Present at Rodman & Renshaw Annual China Investment Conference 6Health News:Yongye International to Present at Rodman & Renshaw Annual China Investment Conference 7Health News:Yongye International to Present at Rodman & Renshaw Annual China Investment Conference 8Health News:Yongye International to Present at Rodman & Renshaw Annual China Investment Conference 9Health News:Twenty-Five Years of HIV Blood Testing Helped to Positively Transform Global Health Crisis 2Health News:Twenty-Five Years of HIV Blood Testing Helped to Positively Transform Global Health Crisis 3Health News:Twenty-Five Years of HIV Blood Testing Helped to Positively Transform Global Health Crisis 4Health News:Twenty-Five Years of HIV Blood Testing Helped to Positively Transform Global Health Crisis 5Health News:Twenty-Five Years of HIV Blood Testing Helped to Positively Transform Global Health Crisis 6Health News:Twenty-Five Years of HIV Blood Testing Helped to Positively Transform Global Health Crisis 7Health News:Twenty-Five Years of HIV Blood Testing Helped to Positively Transform Global Health Crisis 8Health News:Twenty-Five Years of HIV Blood Testing Helped to Positively Transform Global Health Crisis 9Health News:Twenty-Five Years of HIV Blood Testing Helped to Positively Transform Global Health Crisis 10Health News:Twenty-Five Years of HIV Blood Testing Helped to Positively Transform Global Health Crisis 11Health News:Twenty-Five Years of HIV Blood Testing Helped to Positively Transform Global Health Crisis 12
Selute Picotip Atrial-J steroid eluting passive fixation lead...
The VascoTip J 9/60 PU is a unipolar tined, J-preformed permanent pacing lead. Due to advanced technology, VascoTip J 9/60 PU M is compatible to all pacemaker-cavities with the size of IS-1 (3.2 mm),...
VascoTip is a unipolar tined permanent pacing lead. Due to advanced technology, VascoTip 9/60 M is compatible to all pacemaker-cavities with the size of IS-1 (3.2 mm), 5 mm, 6 mm....
VascoTip is a unipolar tined permanent pacing lead. Due to advanced technology, VascoTip 9/60 M is compatible to all pacemaker-cavities with the size of IS-1 (3.2 mm), 5 mm, 6 mm....
Medicine Products: